Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Ariel Finkelstein; Sabina Izraelov; Arie Roth; Sigal Ben-Shmuel; Gad Keren; Hylton Miller; Jacob George

doi:10.1080/14628840410030496

Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Ariel Finkelstein, Sabina Izraelov, Arie Roth, Sigal Ben-Shmuel, Gad Keren, Hylton Miller, Jacob George^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.

Original language	English
Pages (from-to)	107-109
Number of pages	3
Journal	International Journal of Cardiovascular Interventions
Volume	6
Issue number	3-4
DOIs	https://doi.org/10.1080/14628840410030496
State	Published - 2004

Keywords

Eptifibatide
Immune system
Lymphocyte activation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14628840410030496

Cite this

@article{e996fa688b6242ff8ef45e8ec6f7ec61,

title = "Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty",

abstract = "Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.",

keywords = "Eptifibatide, Immune system, Lymphocyte activation",

author = "Ariel Finkelstein and Sabina Izraelov and Arie Roth and Sigal Ben-Shmuel and Gad Keren and Hylton Miller and Jacob George",

year = "2004",

doi = "10.1080/14628840410030496",

language = "אנגלית",

volume = "6",

pages = "107--109",

journal = "International Journal of Cardiovascular Interventions",

issn = "1462-8848",

publisher = "Taylor and Francis Ltd.",

number = "3-4",

}

TY - JOUR

T1 - Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

AU - Finkelstein, Ariel

AU - Izraelov, Sabina

AU - Roth, Arie

AU - Ben-Shmuel, Sigal

AU - Keren, Gad

AU - Miller, Hylton

AU - George, Jacob

PY - 2004

Y1 - 2004

N2 - Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.

AB - Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents.

KW - Eptifibatide

KW - Immune system

KW - Lymphocyte activation

UR - http://www.scopus.com/inward/record.url?scp=10844228323&partnerID=8YFLogxK

U2 - 10.1080/14628840410030496

DO - 10.1080/14628840410030496

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:10844228323

SN - 1462-8848

VL - 6

SP - 107

EP - 109

JO - International Journal of Cardiovascular Interventions

JF - International Journal of Cardiovascular Interventions

IS - 3-4

ER -

Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this